Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer

Journal of Clinical Oncology

Volumn 24, Issue 13, 2006, Pages 2052-2058

  Tolcher, Anthony W ^a   Hao, Desiree ^a   De Bono, Johann ^a   Miller, Alex ^a   Patnaik, Amita ^a   Hammond, Lisa A ^a   Smetzer, Leslie ^a   Van Wart Hood, Jill ^a   Merritt, James ^a   Rowinsky, Eric K ^a   Takimoto, Chris ^a   Von Hoff, Dan ^a   Eckhardt, S Gail ^a  

^a CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; FIBRIN DEGRADATION PRODUCT; PROTEIN P53; DNA; VIRUS ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; DIARRHEA; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG SAFETY; DRUG UPTAKE; FATIGUE; FEMALE; FEVER; FIBRINOGEN BLOOD LEVEL; GENE THERAPY; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RIGOR; SIDE EFFECT; SKIN BIOPSY; THROMBOCYTOPENIA; TUMOR BIOPSY; URINALYSIS; VIRUS PARTICLE; VOMITING; BLOOD; BLOOD CLOTTING; DRUG EFFECT; GENE VECTOR; GENETICS; HUMAN ADENOVIRUS; MIDDLE AGED; NEOPLASM; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

ADENOVIRUSES, HUMAN; ADULT; AGED; ANTIBODIES, VIRAL; BLOOD COAGULATION; CYTOMEGALOVIRUS; DNA; FEMALE; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PARTIAL THROMBOPLASTIN TIME; PROMOTER REGIONS (GENETICS);

EID: 33646457691     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.03.6756     Document Type: Article

References (28)

1. Baker SJ, Fearon ER, Nigro JM, et al: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217-221, 1989
2. Isobe M, Emanuel BS, Givol D, et al: Localization of gene for human p53 tumour antigen to band 17p13. Nature 320:84-85, 1986
3. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature 351:453-456, 1991
4. Halevy O, Michalovitz D, Oren M: Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250:113-116, 1990
5. Malkin D, Li FP, Strong LC, et al: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990
6. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
7. Takahashi T, Nau MM, Chiba I, et al: p53: a frequent target for genetic abnormalities in lung cancer. Science 246:491-494, 1989
8. Sidransky D, Von Eschenbach A, Tsai YC, et al: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706-709, 1991
9. Nigro JM, Baker SJ, Preisinger AC, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708, 1989
10. Zhang WW, Fang X, Mazur W, et al: High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5-13, 1994
11. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291, 1994
12. Shono T, Tofilon PJ, Schaefer TS, et al: Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res 62:1069-1076, 2002
13. Wang J, Bucana CD, Roth JA, et al: Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 2:9-17, 1995
14. Liu TJ, Zhang WW, Taylor DL, et al: Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54:3662-3667, 1994
15. Clayman GL, el-Naggar AK, Roth JA, et al: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 55:1-6, 1995
16. Nemunaitis J, Swisher SG, Timmons T, et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18:609-622, 2000
17. Clayman GL, el-Naggar AK, Lippman SM, et al: Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 16:2221-2232, 1998
18. Swisher SG, Roth JA, Nemunaitis J, et al: Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 91: 763-771, 1999
19. Swisher SG, Roth JA, Komaki R, et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res 9:93-101, 2003
20. Wolf JK, Bodurka DC, Gano JB, et al: A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol 94:442-448, 2004
21. Saulnier P, Vidaud M, Gautier E, et al: Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201). J Virol Meth 114:55-64, 2003
22. Lang FF, Bruner JM, Fuller GN, et al: Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 21:2508-2518, 2003
23. Nemunaitis J, Cunningham C, Buchanan A, et al: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther 8:746-759, 2001
24. Raper SE, Chirmule N, Lee FS, et al: Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genetics Metab 80:148, 2003
25. Rusch V, Klimstra D, Venkatraman E, et al: Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038-5042, 1995
26. Anthoney DA, McIlwrath AJ, Gallagher WM, et al: Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56:1374-1381, 1996
27. Perego P, Giarola M, Righetti SC, et al: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56:556-562, 1996
28. Berns EM, Foekens JA, Vossen R, et al: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 60:2155-2162, 2000